This is the authors' abstract. We don't add key points for this paper.
Mycotoxins are synthesized by various fungal species and are known to exert toxic effects on vertebrates and other animals, even at low concentrations. However, the current countermeasure for mycotoxin contamination is random inspection of samples prior to shipment. In this study, we focused on Chlorella sorokiniana (CS) from Ishigaki Island, Japan, and examined its ability to detoxify deoxynivalenol (DON), ochratoxin A (OTA), and fumonisin B1 (FB1) in vitro and in vivo. The binding of CS to DON, OTA, and FB1 was evaluated in vitro. The detoxification of CS was demonstrated by monitoring its concentrations in the plasma and urine samples of male ICR mice. Plasma and urine samples were collected 30 min, 2 h, and 24 h after an oral administration of 5 mg/kg mycotoxins and/or 500 mg/kg CS. CS bound to more than 80% and 40% of DON and OTA, respectively, whereas the binding of CS to FB1 was less than 10%. The concentrations of DON and OTA in plasma and urine samples were substantially reduced by CS co-administration, whereas CS did not affect FB1 absorption. The co-administration of CS substantially inhibited the systemic absorption of DON and OTA.
No takes yet. Share an insight, caveat, or question.
Yamaguchi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: